Most Read

Eli Lilly and Company is set to acquire the remaining shares of biotech firm Protomer Technologies in a deal valued more than $1bn. The latest move follows Lilly’s

Biotechnology company Prime Medicine has launched with $315m funding to advance its Prime Editing platform, a next-generation gene editing technology. The financing includes a $115m in series A

The Russian Direct Investment Fund (RDIF) has collaborated with Serum Institute of India (SII) to produce Sputnik V Covid-19 vaccine in India. RDIF and SII plan to produce

Danish pharma company Novo Nordisk has agreed to acquire Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme for a deal valued at $1.2bn. Under the terms

Philip Morris International (PMI) has agreed to acquire British pharmaceutical firm Vectura Group for about $1.183bn (£852m) to expand its product pipeline development capabilities in inhaled therapeutics. The

Verge Genomics has announced a three-year partnership with Eli Lilly and Company to discover and develop novel therapies for amyotrophic lateral sclerosis (ALS), a motor neuron disease. As

The US Food and Drug Administration (FDA) has accepted the biologics licence application (BLA) and granted priority review for tezepelumab, which is being developed by AstraZeneca and Amgen,

Altesa Biosciences has signed an exclusive worldwide license agreement with biotechnology firm Vaxart for the development and commercialisation of the latter’s patented formulation of the capsid-binding Vapendavir antiviral.

Eureka Therapeutics and Memorial Sloan Kettering Cancer Center (MSK) have signed a new G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) license agreement with Sanofi to